CLINICAL RESEARCH ON THE EFFICACY OF TACE IN COMBINATION WITH INJECTION OF ARSENIC TRIOXIDE ON PRIMARY HEPATOCARCINOMA
Deshuang Xiao,Chenhong Zhu,Zhijian Zheng,Honggen Xu,Yinghao Jiang,Tianfu Wen,Chenyang Mao,Qiang Wang,Lingbo Dai
DOI: https://doi.org/10.19193/0393-6384_2019_3_249
2019-01-01
Acta medica mediterranea
Abstract:Objective: To observe the clinical efficacy of transcatheter arterial chemoembolization (TACE) in combination with injection of arsenic trioxide on the primary hepatocarcinoma. Methods: We selected a total of 156 patients with primary hepatic carcinoma that were not available to perform surgical resection and received treatment in this hospital between January and December in 2017. According to the treatment strategy, patients were divided into two groups, i.e. the observation group and the control group, with 78 in each group. In the observation group, patients received one cycle of intravenous injection of 10 mg arsenic trioxide dissolved in 500 mL normal saline for consecutive 7 days, followed by 10 days of recovery, and treatment lasted for 4 cycles; additionally, TACE treatment was performed with 40 mg epirubicin and 10 mL ultra-fluid lipiodol, i.e. after emulsification, drugs were delivered into the vessels that.supplied blood surrounding the tumors; one cycle of TACE treatment consisted of 4 to 8 weeks. In the control group, patients only underwent TACE treatment that was same as the observation group. After 3 cycles of TACE, we evaluated the efficacy, survival rates, life quality and adverse reactions at 0.5, 1 and 2 years. Results: The effective rates in the observation group and the control group were 70.51% (55/78) and 57.69% (45/78), respectively, and the difference between two groups showed statistical significance (p<0.05). Between the observation group and the control group, comparisons of the median of survival (837 vs. 8.12 months), average of survival (12.97 vs. 8.79 months) and survival rate at 0.5 year (88.46% vs. 83.33%) showed no statistically significant difference (p>0.05). However, one- and two-year survival rates in the observation group were significantly higher than those in the control group (one-year survival rate: 62.82% vs. 44.87%; two-year survival rate: 26.92% vs. 17.95%; p<0.05).The improvement rate in the observation group was 76.92%, also significantly higher than 55.12% in the control group (p<0.05). Adverse reactions, including increases in glutamic oxalacetic transaminase and glutamic-pyruvic transatninase, decreases in albumin, and anomaly in bilirubin and echocardiography, were seen in two groups, and the differences had statistical significance (p<0.05). Conclusion: TACE in combination with intravenous injection of arsenic trioxide gains promising efficacy on primary hepatic carcinoma, which can improve the survival and life quality of patients, and ameliorate the adverse reactions of treatment. Thus, it has a critical value in clinical practice.